Roche firm on Genentech offer

Deal-watchers, take comfort. Roche says it's standing by its $43.7 billion offer to buy the rest of Genentech it doesn't own. Yes, there's been little activity on that deal lately, but Roche says it's still hungry for the buyout--and because Genentech shares have dropped below the $89 offer price, it might just decide to deal. Report

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

Warren Buffett's Berkshire Hathaway has built a $192 million stake in Biogen, a risky investment considering aducanumab's uncertain future.